Skip to main content
Erschienen in: Journal of Mammary Gland Biology and Neoplasia 4/2020

04.11.2020 | Obesity

Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools

verfasst von: Erin D. Giles, Elizabeth A. Wellberg

Erschienen in: Journal of Mammary Gland Biology and Neoplasia | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Obesity increases the risk for breast cancer and is associated with poor outcomes for cancer patients. A variety of rodent models have been used to investigate these relationships; however, key differences in experimental approaches, as well as unique aspects of rodent physiology lead to variability in how these valuable models are implemented. We combine expertise in the development and implementation of preclinical models of obesity and breast cancer to disseminate effective practices for studies that integrate these fields. In this review, we share, based on our experience, key considerations for model selection, highlighting important technical nuances and tips for use of preclinical models in studies that integrate obesity with breast cancer risk and progression. We describe relevant mouse and rat paradigms, specifically highlighting differences in breast tumor subtypes, estrogen production, and strategies to manipulate hormone levels. We also outline options for diet composition and housing environments to promote obesity in female rodents. While we have applied our experience to understanding obesity-associated breast cancer, the experimental variables we incorporate have relevance to multiple fields that investigate women’s health.
Literatur
1.
Zurück zum Zitat Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–91. PubMed Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–91. PubMed
2.
Zurück zum Zitat Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;(288):1–8 Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;(288):1–8
3.
Zurück zum Zitat Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. PubMedPubMedCentral Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. PubMedPubMedCentral
4.
Zurück zum Zitat Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14. PubMedPubMedCentral Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14. PubMedPubMedCentral
5.
Zurück zum Zitat Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–21. PubMedPubMedCentral Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–21. PubMedPubMedCentral
6.
Zurück zum Zitat Matthews SB, Thompson HJ. The obesity-breast cancer conundrum: an analysis of the issues. Int J Mol Sci. 2016;17(6):989. PubMedCentral Matthews SB, Thompson HJ. The obesity-breast cancer conundrum: an analysis of the issues. Int J Mol Sci. 2016;17(6):989. PubMedCentral
7.
Zurück zum Zitat Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL, et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 2016;157(3):545–54. PubMedPubMedCentral Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL, et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 2016;157(3):545–54. PubMedPubMedCentral
8.
Zurück zum Zitat Park YM, White AJ, Nichols HB, O’Brien KM, Weinberg CR, Sandler DP. The association between metabolic health, obesity phenotype and the risk of breast cancer. Int J Cancer. 2017;140(12):2657–66. PubMedPubMedCentral Park YM, White AJ, Nichols HB, O’Brien KM, Weinberg CR, Sandler DP. The association between metabolic health, obesity phenotype and the risk of breast cancer. Int J Cancer. 2017;140(12):2657–66. PubMedPubMedCentral
9.
Zurück zum Zitat Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97. PubMedPubMedCentral Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97. PubMedPubMedCentral
10.
Zurück zum Zitat Azvolinsky A. Cancer risk: the fat tissue-BMI-obesity connection. J Natl Cancer Inst. 2014;106(4):dju100. PubMed Azvolinsky A. Cancer risk: the fat tissue-BMI-obesity connection. J Natl Cancer Inst. 2014;106(4):dju100. PubMed
11.
Zurück zum Zitat Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. PubMedPubMedCentral Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. PubMedPubMedCentral
12.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. PubMed Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. PubMed
13.
Zurück zum Zitat Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7. PubMedPubMedCentral Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7. PubMedPubMedCentral
14.
Zurück zum Zitat Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. PubMed Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. PubMed
15.
Zurück zum Zitat Heshmati K, Harris DA, Rosner B, Pranckevicius E, Ardestani A, Cho N, et al. Association of bariatric surgery status with reduced HER2+ breast cancers: a retrospective cohort study. Obes Surg. 2019;29(4):1092–8. PubMed Heshmati K, Harris DA, Rosner B, Pranckevicius E, Ardestani A, Cho N, et al. Association of bariatric surgery status with reduced HER2+ breast cancers: a retrospective cohort study. Obes Surg. 2019;29(4):1092–8. PubMed
16.
Zurück zum Zitat Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, et al. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumabemtansine. Real-world evidence J Cell Physiol. 2020;235(11):7900–10. PubMed Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, et al. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumabemtansine. Real-world evidence J Cell Physiol. 2020;235(11):7900–10. PubMed
17.
Zurück zum Zitat Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating tumor characteristics to the American joint committee on cancer breast cancer staging system. Oncologist. 2017;22(11):1292–300. PubMedPubMedCentral Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating tumor characteristics to the American joint committee on cancer breast cancer staging system. Oncologist. 2017;22(11):1292–300. PubMedPubMedCentral
18.
Zurück zum Zitat Torres-de la Roche LA, Steljes I, Janni W, Friedl TWP, De Wilde RL. The association between obesity and premenopausal breast cancer according to intrinsic subtypes - a systematic review. Geburtshilfe Frauenheilkd. 2020;80(6):601–10. PubMedPubMedCentral Torres-de la Roche LA, Steljes I, Janni W, Friedl TWP, De Wilde RL. The association between obesity and premenopausal breast cancer according to intrinsic subtypes - a systematic review. Geburtshilfe Frauenheilkd. 2020;80(6):601–10. PubMedPubMedCentral
19.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95. PubMedPubMedCentral Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95. PubMedPubMedCentral
20.
Zurück zum Zitat Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46. PubMedPubMedCentral Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46. PubMedPubMedCentral
21.
Zurück zum Zitat Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–5. PubMed Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–5. PubMed
22.
Zurück zum Zitat Folkerd EJ, Dixon JM, Renshaw L, A’Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30(24):2977–80. PubMed Folkerd EJ, Dixon JM, Renshaw L, A’Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30(24):2977–80. PubMed
23.
Zurück zum Zitat Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012;30(24):2940–2. PubMed Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012;30(24):2940–2. PubMed
24.
Zurück zum Zitat Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex study group. Cancer. 1997;79(4):730–9. PubMed Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex study group. Cancer. 1997;79(4):730–9. PubMed
25.
Zurück zum Zitat Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996;32A(3):404–12. PubMed Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996;32A(3):404–12. PubMed
26.
Zurück zum Zitat Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, et al. Letrozole suppresses plasma estradiol and estronesulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671–6. PubMed Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, et al. Letrozole suppresses plasma estradiol and estronesulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671–6. PubMed
27.
Zurück zum Zitat Elliott MJ, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, et al. Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. NPJ Breast Cancer. 2020;6:22. PubMedPubMedCentral Elliott MJ, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, et al. Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. NPJ Breast Cancer. 2020;6:22. PubMedPubMedCentral
28.
Zurück zum Zitat Ozdemir BC, Sflomos G, Brisken C. The challenges of modeling hormone receptor-positive breast cancer in mice. Endocr Relat Cancer. 2018;25(5):R319–30. PubMed Ozdemir BC, Sflomos G, Brisken C. The challenges of modeling hormone receptor-positive breast cancer in mice. Endocr Relat Cancer. 2018;25(5):R319–30. PubMed
29.
Zurück zum Zitat Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res. 1985;45(8):3415–43. PubMed Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res. 1985;45(8):3415–43. PubMed
30.
Zurück zum Zitat Thompson HJ. Methods for the induction of mammary carcinogenesis in the rat using either 7,12-Dimethylbenz[α]anthracene or 1-Methyl-1-Nitrosourea. In: Ip M.M. ABB, editor. Methods in mammary gland biology and breast cancer research. Boston: Springer; 2000. p. 19–29. Thompson HJ. Methods for the induction of mammary carcinogenesis in the rat using either 7,12-Dimethylbenz[α]anthracene or 1-Methyl-1-Nitrosourea. In: Ip M.M. ABB, editor. Methods in mammary gland biology and breast cancer research. Boston: Springer; 2000. p. 19–29.
31.
Zurück zum Zitat Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis. 1995;16(10):2407–11. PubMed Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis. 1995;16(10):2407–11. PubMed
32.
Zurück zum Zitat Perse M, Cerar A, Injac R, Strukelj B. N-methylnitrosourea induced breast cancer in rat, the histopathology of the resulting tumours and its drawbacks as a model. Pathol Oncol Res. 2009;15(1):115–21. PubMed Perse M, Cerar A, Injac R, Strukelj B. N-methylnitrosourea induced breast cancer in rat, the histopathology of the resulting tumours and its drawbacks as a model. Pathol Oncol Res. 2009;15(1):115–21. PubMed
33.
Zurück zum Zitat McCormick DL, Adamowski CB, Fiks A, Moon RC. Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res. 1981;41(5):1690–4. PubMed McCormick DL, Adamowski CB, Fiks A, Moon RC. Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res. 1981;41(5):1690–4. PubMed
34.
Zurück zum Zitat MacLean PS, Giles ED, Johnson GC, McDaniel SM, Fleming-Elder BK, Gilman KA, et al. A surprising link between the energetics of ovariectomy-induced weight gain and mammary tumor progression in obese rats. Obesity (Silver Spring). 2010;18(4):696–703. MacLean PS, Giles ED, Johnson GC, McDaniel SM, Fleming-Elder BK, Gilman KA, et al. A surprising link between the energetics of ovariectomy-induced weight gain and mammary tumor progression in obese rats. Obesity (Silver Spring). 2010;18(4):696–703.
35.
Zurück zum Zitat Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, et al. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012;72(24):6490–501. PubMedPubMedCentral Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, et al. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012;72(24):6490–501. PubMedPubMedCentral
36.
Zurück zum Zitat Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018;20(1):50. PubMedPubMedCentral Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018;20(1):50. PubMedPubMedCentral
37.
Zurück zum Zitat Giles ED, Jackman MR, MacLean PS. Modeling diet-induced obesity with obesity-prone rats: implications for studies in females. Front Nutr. 2016;3:50. PubMedPubMedCentral Giles ED, Jackman MR, MacLean PS. Modeling diet-induced obesity with obesity-prone rats: implications for studies in females. Front Nutr. 2016;3:50. PubMedPubMedCentral
38.
Zurück zum Zitat Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, et al. Metformin accumulation correlates with organic cation transporter 2 protein expression and predicts mammary tumor regression in vivo. Cancer Prev Res (Phila). 2017;10(3):198–207. Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, et al. Metformin accumulation correlates with organic cation transporter 2 protein expression and predicts mammary tumor regression in vivo. Cancer Prev Res (Phila). 2017;10(3):198–207.
39.
Zurück zum Zitat Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, et al. The androgen receptor supports tumor progression after the loss of ovarian function in a preclinical model of obesity and breast cancer. Horm Cancer. 2017;8(5–6):269–85. PubMedPubMedCentral Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, et al. The androgen receptor supports tumor progression after the loss of ovarian function in a preclinical model of obesity and breast cancer. Horm Cancer. 2017;8(5–6):269–85. PubMedPubMedCentral
40.
Zurück zum Zitat Thompson HJ, McGinley JN, Wolfe P, Singh M, Steele VE, Kelloff GJ. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis. 1998;19(12):2181–5. PubMed Thompson HJ, McGinley JN, Wolfe P, Singh M, Steele VE, Kelloff GJ. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis. 1998;19(12):2181–5. PubMed
41.
Zurück zum Zitat Thompson HJ, Adlakha H, Singh M. Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis. 1992;13(9):1535–9. PubMed Thompson HJ, Adlakha H, Singh M. Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis. 1992;13(9):1535–9. PubMed
42.
Zurück zum Zitat Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 1991;51(13):3411–5. PubMed Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 1991;51(13):3411–5. PubMed
43.
Zurück zum Zitat Hennighausen L. Mouse models for breast cancer. Oncogene. 2000;19(8):966–7. PubMed Hennighausen L. Mouse models for breast cancer. Oncogene. 2000;19(8):966–7. PubMed
44.
Zurück zum Zitat Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene. 2000;19(53):6130–7. PubMed Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene. 2000;19(53):6130–7. PubMed
45.
Zurück zum Zitat Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv. 2017;3(4):e1600957. PubMedPubMedCentral Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv. 2017;3(4):e1600957. PubMedPubMedCentral
46.
Zurück zum Zitat Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–41. PubMed Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–41. PubMed
47.
Zurück zum Zitat Evangelista GCM, Salvador PA, Soares SMA, Barros LRC, Xavier F, Abdo LM, et al. 4T1 Mammary carcinoma colonization of metastatic niches is accelerated by obesity. Front Oncol. 2019;9:685. PubMedPubMedCentral Evangelista GCM, Salvador PA, Soares SMA, Barros LRC, Xavier F, Abdo LM, et al. 4T1 Mammary carcinoma colonization of metastatic niches is accelerated by obesity. Front Oncol. 2019;9:685. PubMedPubMedCentral
48.
Zurück zum Zitat Kirma NB, Tekmal RR. Transgenic mouse models of hormonal mammary carcinogenesis: advantages and limitations. J Steroid Biochem Mol Biol. 2012;131(3–5):76–82. PubMed Kirma NB, Tekmal RR. Transgenic mouse models of hormonal mammary carcinogenesis: advantages and limitations. J Steroid Biochem Mol Biol. 2012;131(3–5):76–82. PubMed
49.
Zurück zum Zitat Usary J, Darr DB, Pfefferle AD, Perou CM. Overview of genetically engineered mouse models of distinct breast cancer subtypes. Curr Protoc Pharmacol. 2016;72:14 38 1-14 38 11. Usary J, Darr DB, Pfefferle AD, Perou CM. Overview of genetically engineered mouse models of distinct breast cancer subtypes. Curr Protoc Pharmacol. 2016;72:14 38 1-14 38 11.
50.
Zurück zum Zitat Jallow F, Brockman JL, Helzer KT, Rugowski DE, Goffin V, Alarid ET, et al. 17beta-Estradiol and ICI182,780 differentially regulate STAT5 isoforms in female mammary epithelium, with distinct outcomes. J Endocr Soc. 2018;2(3):293–309. PubMedPubMedCentral Jallow F, Brockman JL, Helzer KT, Rugowski DE, Goffin V, Alarid ET, et al. 17beta-Estradiol and ICI182,780 differentially regulate STAT5 isoforms in female mammary epithelium, with distinct outcomes. J Endocr Soc. 2018;2(3):293–309. PubMedPubMedCentral
51.
Zurück zum Zitat Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene. 2003;22(30):4664–74. PubMedPubMedCentral Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene. 2003;22(30):4664–74. PubMedPubMedCentral
52.
Zurück zum Zitat Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, et al. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol. 2003;163(5):1713–9. PubMedPubMedCentral Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, et al. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol. 2003;163(5):1713–9. PubMedPubMedCentral
53.
Zurück zum Zitat Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res. 2012;14(1):R16. PubMedPubMedCentral Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res. 2012;14(1):R16. PubMedPubMedCentral
54.
Zurück zum Zitat Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia. 1999;4(1):105–22. PubMed Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia. 1999;4(1):105–22. PubMed
55.
Zurück zum Zitat Fleming JM, Long EL, Ginsburg E, Gerscovich D, Meltzer PS, Vonderhaar BK. Interlobular and intralobular mammary stroma: genotype may not reflect phenotype. BMC Cell Biol. 2008;9:46. PubMedPubMedCentral Fleming JM, Long EL, Ginsburg E, Gerscovich D, Meltzer PS, Vonderhaar BK. Interlobular and intralobular mammary stroma: genotype may not reflect phenotype. BMC Cell Biol. 2008;9:46. PubMedPubMedCentral
56.
Zurück zum Zitat Dankort DL, Muller WJ. Transgenic models of breast cancer metastasis. Cancer Treat Res. 1996;83:71–88. PubMed Dankort DL, Muller WJ. Transgenic models of breast cancer metastasis. Cancer Treat Res. 1996;83:71–88. PubMed
57.
Zurück zum Zitat Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016;35(4):547–73. PubMedPubMedCentral Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016;35(4):547–73. PubMedPubMedCentral
58.
Zurück zum Zitat Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, et al. A preclinical model for ERalpha-Positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell. 2016;29(3):407–22. PubMed Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, et al. A preclinical model for ERalpha-Positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell. 2016;29(3):407–22. PubMed
59.
Zurück zum Zitat Matthews SB, Sartorius CA. Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm Cancer. 2017;8(1):4–15. PubMed Matthews SB, Sartorius CA. Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm Cancer. 2017;8(1):4–15. PubMed
60.
Zurück zum Zitat Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020;22(1):68. PubMedPubMedCentral Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020;22(1):68. PubMedPubMedCentral
61.
Zurück zum Zitat Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer. 2008;60(4):534–41. PubMed Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer. 2008;60(4):534–41. PubMed
62.
Zurück zum Zitat Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, et al. Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord. 2002;26(12):1596–609. PubMed Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, et al. Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord. 2002;26(12):1596–609. PubMed
63.
Zurück zum Zitat Kleinert M, Clemmensen C, Hofmann SM, Moore MC, Renner S, Woods SC, et al. Animal models of obesity and diabetes mellitus. Nat Rev Endocrinol. 2018;14(3):140–62. PubMed Kleinert M, Clemmensen C, Hofmann SM, Moore MC, Renner S, Woods SC, et al. Animal models of obesity and diabetes mellitus. Nat Rev Endocrinol. 2018;14(3):140–62. PubMed
64.
Zurück zum Zitat Speakman J, Hambly C, Mitchell S, Krol E. The contribution of animal models to the study of obesity. Lab Anim. 2008;42(4):413–32. PubMed Speakman J, Hambly C, Mitchell S, Krol E. The contribution of animal models to the study of obesity. Lab Anim. 2008;42(4):413–32. PubMed
65.
Zurück zum Zitat Tschop M, Heiman ML. Overview of rodent models for obesity research. Curr Protoc Neurosci. 2002;Chapter 9:Unit 9 10. Tschop M, Heiman ML. Overview of rodent models for obesity research. Curr Protoc Neurosci. 2002;Chapter 9:Unit 9 10.
66.
Zurück zum Zitat Gunter MJ, Xie X, Xue X, Kabat GC, Rohan TE, Wassertheil-Smoller S, et al. Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res. 2015;75(2):270–4. PubMedPubMedCentral Gunter MJ, Xie X, Xue X, Kabat GC, Rohan TE, Wassertheil-Smoller S, et al. Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res. 2015;75(2):270–4. PubMedPubMedCentral
67.
Zurück zum Zitat Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, et al. Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1730–5. PubMedPubMedCentral Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, et al. Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1730–5. PubMedPubMedCentral
68.
Zurück zum Zitat Chlebowski RT, Aragaki AK, Anderson GL, Thomson CA, Manson JE, Simon MS, et al. Low-fat dietary pattern and breast cancer mortality in the women’s health initiative randomized controlled trial. J Clin Oncol. 2017;35(25):2919–26. PubMedPubMedCentral Chlebowski RT, Aragaki AK, Anderson GL, Thomson CA, Manson JE, Simon MS, et al. Low-fat dietary pattern and breast cancer mortality in the women’s health initiative randomized controlled trial. J Clin Oncol. 2017;35(25):2919–26. PubMedPubMedCentral
69.
Zurück zum Zitat Chlebowski RT, Anderson GL, Manson JE, Prentice RL, Aragaki AK, Snetselaar L, et al. Low-fat dietary pattern and cancer mortality in the women’s health initiative (WHI) randomized controlled trial. JNCI Cancer Spectr. 2018;2(4):pky065. PubMed Chlebowski RT, Anderson GL, Manson JE, Prentice RL, Aragaki AK, Snetselaar L, et al. Low-fat dietary pattern and cancer mortality in the women’s health initiative (WHI) randomized controlled trial. JNCI Cancer Spectr. 2018;2(4):pky065. PubMed
70.
Zurück zum Zitat Chlebowski RT, Aragaki AK, Anderson GL, Simon MS, Manson JE, Neuhouser ML, et al. Association of low-fat dietary pattern with breast cancer overall survival: a secondary analysis of the women’s health initiative randomized clinical trial. JAMA Oncol. 2018;4(10):e181212. PubMedPubMedCentral Chlebowski RT, Aragaki AK, Anderson GL, Simon MS, Manson JE, Neuhouser ML, et al. Association of low-fat dietary pattern with breast cancer overall survival: a secondary analysis of the women’s health initiative randomized clinical trial. JAMA Oncol. 2018;4(10):e181212. PubMedPubMedCentral
71.
Zurück zum Zitat Chlebowski RT, Aragaki AK, Anderson GL, Pan K, Neuhouser ML, Manson JE, et al. Dietary modification and breast cancer mortality: long-term follow-up of the women’s health initiative randomized trial. J Clin Oncol. 2020;38(13):1419–28. PubMed Chlebowski RT, Aragaki AK, Anderson GL, Pan K, Neuhouser ML, Manson JE, et al. Dietary modification and breast cancer mortality: long-term follow-up of the women’s health initiative randomized trial. J Clin Oncol. 2020;38(13):1419–28. PubMed
72.
Zurück zum Zitat Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, et al. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018;3(14):e120594. PubMedCentral Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, et al. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018;3(14):e120594. PubMedCentral
73.
Zurück zum Zitat Giles ED, Jackman MR, Johnson GC, Schedin PJ, Houser JL, MacLean PS. Effect of the estrous cycle and surgical ovariectomy on energy balance, fuel utilization, and physical activity in lean and obese female rats. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):R1634–42. PubMedPubMedCentral Giles ED, Jackman MR, Johnson GC, Schedin PJ, Houser JL, MacLean PS. Effect of the estrous cycle and surgical ovariectomy on energy balance, fuel utilization, and physical activity in lean and obese female rats. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):R1634–42. PubMedPubMedCentral
74.
Zurück zum Zitat Sherk VD, Jackman MR, Giles ED, Higgins JA, Foright RM, Presby DM, et al. Prior weight loss exacerbates the biological drive to gain weight after the loss of ovarian function. Physiol Rep. 2017;5(10):e13272. PubMedPubMedCentral Sherk VD, Jackman MR, Giles ED, Higgins JA, Foright RM, Presby DM, et al. Prior weight loss exacerbates the biological drive to gain weight after the loss of ovarian function. Physiol Rep. 2017;5(10):e13272. PubMedPubMedCentral
75.
Zurück zum Zitat Sherk VD, Jackman MR, Higgins JA, Giles ED, Foright RM, Presby DM, et al. Impact of exercise and activity on weight regain and musculoskeletal health post-ovariectomy. Med Sci Sports Exerc. 2019;51(12):2465–73. PubMedPubMedCentral Sherk VD, Jackman MR, Higgins JA, Giles ED, Foright RM, Presby DM, et al. Impact of exercise and activity on weight regain and musculoskeletal health post-ovariectomy. Med Sci Sports Exerc. 2019;51(12):2465–73. PubMedPubMedCentral
76.
Zurück zum Zitat Fischer AW, Cannon B, Nedergaard J. The answer to the question “What is the best housing temperature to translate mouse experiments to humans?” is: thermoneutrality. Mol Metab. 2019;26:1–3. PubMedPubMedCentral Fischer AW, Cannon B, Nedergaard J. The answer to the question “What is the best housing temperature to translate mouse experiments to humans?” is: thermoneutrality. Mol Metab. 2019;26:1–3. PubMedPubMedCentral
77.
78.
Zurück zum Zitat Keijer J, Li M, Speakman JR. What is the best housing temperature to translate mouse experiments to humans? Mol Metab. 2019a;25:168–76. PubMedPubMedCentral Keijer J, Li M, Speakman JR. What is the best housing temperature to translate mouse experiments to humans? Mol Metab. 2019a;25:168–76. PubMedPubMedCentral
79.
Zurück zum Zitat Keijer J, Li M, Speakman JR. To best mimic human thermal conditions, mice should be housed slightly below thermoneutrality. Mol Metab. 2019b;26:4. PubMedPubMedCentral Keijer J, Li M, Speakman JR. To best mimic human thermal conditions, mice should be housed slightly below thermoneutrality. Mol Metab. 2019b;26:4. PubMedPubMedCentral
80.
Zurück zum Zitat Speakman JR, Keijer J. Not so hot: Optimal housing temperatures for mice to mimic the thermal environment of humans. Mol Metab. 2012;2(1):5–9. PubMedPubMedCentral Speakman JR, Keijer J. Not so hot: Optimal housing temperatures for mice to mimic the thermal environment of humans. Mol Metab. 2012;2(1):5–9. PubMedPubMedCentral
81.
Zurück zum Zitat Gordon CJ. Thermal physiology of laboratory mice: defining thermoneutrality. J Therm Biol. 2012;37(8):654–85. Gordon CJ. Thermal physiology of laboratory mice: defining thermoneutrality. J Therm Biol. 2012;37(8):654–85.
82.
Zurück zum Zitat Morris EM, Noland RD, Allen JA, McCoin CS, Xia Q, Koestler DC, et al. Difference in housing temperature-induced energy expenditure elicits sex-specific diet-induced metabolic adaptations in mice. Obesity (Silver Spring). 2020;28(10):1922–31. Morris EM, Noland RD, Allen JA, McCoin CS, Xia Q, Koestler DC, et al. Difference in housing temperature-induced energy expenditure elicits sex-specific diet-induced metabolic adaptations in mice. Obesity (Silver Spring). 2020;28(10):1922–31.
83.
Zurück zum Zitat Cui X, Nguyen NL, Zarebidaki E, Cao Q, Li F, Zha L, et al. Thermoneutrality decreases thermogenic program and promotes adiposity in high-fat diet-fed mice. Physiol Rep. 2016;4(10):e12799. PubMedPubMedCentral Cui X, Nguyen NL, Zarebidaki E, Cao Q, Li F, Zha L, et al. Thermoneutrality decreases thermogenic program and promotes adiposity in high-fat diet-fed mice. Physiol Rep. 2016;4(10):e12799. PubMedPubMedCentral
84.
Zurück zum Zitat Hylander BL, Repasky EA. Thermoneutrality, mice, and cancer: A heated opinion. Trends Cancer. 2016;2(4):166–75. PubMed Hylander BL, Repasky EA. Thermoneutrality, mice, and cancer: A heated opinion. Trends Cancer. 2016;2(4):166–75. PubMed
85.
Zurück zum Zitat Ravussin Y, LeDuc CA, Watanabe K, Leibel RL. Effects of ambient temperature on adaptive thermogenesis during maintenance of reduced body weight in mice. Am J Physiol Regul Integr Comp Physiol. 2012;303(4):R438–48. PubMedPubMedCentral Ravussin Y, LeDuc CA, Watanabe K, Leibel RL. Effects of ambient temperature on adaptive thermogenesis during maintenance of reduced body weight in mice. Am J Physiol Regul Integr Comp Physiol. 2012;303(4):R438–48. PubMedPubMedCentral
86.
Zurück zum Zitat Stemmer K, Kotzbeck P, Zani F, Bauer M, Neff C, Muller TD, et al. Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. Int J Obes (Lond). 2015;39(5):791–7. Stemmer K, Kotzbeck P, Zani F, Bauer M, Neff C, Muller TD, et al. Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. Int J Obes (Lond). 2015;39(5):791–7.
87.
Zurück zum Zitat Szymusiak R, Satinoff E. Maximal REM sleep time defines a narrower thermoneutral zone than does minimal metabolic rate. Physiol Behav. 1981;26(4):687–90. PubMed Szymusiak R, Satinoff E. Maximal REM sleep time defines a narrower thermoneutral zone than does minimal metabolic rate. Physiol Behav. 1981;26(4):687–90. PubMed
88.
Zurück zum Zitat Neff EP. A point on thermoneutrality for mice. Lab Animal. 2020;49(6):169. Neff EP. A point on thermoneutrality for mice. Lab Animal. 2020;49(6):169.
89.
Zurück zum Zitat Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology. 2009;150(5):2161–8. PubMedPubMedCentral Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology. 2009;150(5):2161–8. PubMedPubMedCentral
90.
Zurück zum Zitat Witte MM, Resuehr D, Chandler AR, Mehle AK, Overton JM. Female mice and rats exhibit species-specific metabolic and behavioral responses to ovariectomy. Gen Comp Endocrinol. 2010;166(3):520–8. PubMedPubMedCentral Witte MM, Resuehr D, Chandler AR, Mehle AK, Overton JM. Female mice and rats exhibit species-specific metabolic and behavioral responses to ovariectomy. Gen Comp Endocrinol. 2010;166(3):520–8. PubMedPubMedCentral
91.
Zurück zum Zitat Brooks HL, Pollow DP, Hoyer PB. The VCD mouse model of menopause and perimenopause for the study of sex differences in cardiovascular disease and the metabolic syndrome. Physiology (Bethesda). 2016;31(4):250–7. Brooks HL, Pollow DP, Hoyer PB. The VCD mouse model of menopause and perimenopause for the study of sex differences in cardiovascular disease and the metabolic syndrome. Physiology (Bethesda). 2016;31(4):250–7.
92.
Zurück zum Zitat Van Kempen TA, Milner TA, Waters EM. Accelerated ovarian failure: a novel, chemically induced animal model of menopause. Brain Res. 2011;1379:176–87. PubMedPubMedCentral Van Kempen TA, Milner TA, Waters EM. Accelerated ovarian failure: a novel, chemically induced animal model of menopause. Brain Res. 2011;1379:176–87. PubMedPubMedCentral
93.
Zurück zum Zitat Pearse G, Frith J, Randall KJ, Klinowska T. Urinary retention and cystitis associated with subcutaneous estradiol pellets in female nude mice. Toxicol Pathol. 2009;37(2):227–34. PubMed Pearse G, Frith J, Randall KJ, Klinowska T. Urinary retention and cystitis associated with subcutaneous estradiol pellets in female nude mice. Toxicol Pathol. 2009;37(2):227–34. PubMed
94.
Zurück zum Zitat Dall G, Vieusseux J, Unsworth A, Anderson R, Britt K. Low dose, low cost estradiol pellets can support MCF-7 tumour growth in nude mice without bladder symptoms. J Cancer. 2015;6(12):1331–6. PubMedPubMedCentral Dall G, Vieusseux J, Unsworth A, Anderson R, Britt K. Low dose, low cost estradiol pellets can support MCF-7 tumour growth in nude mice without bladder symptoms. J Cancer. 2015;6(12):1331–6. PubMedPubMedCentral
95.
Zurück zum Zitat Eyre R, Alferez DG, Spence K, Kamal M, Shaw FL, Simoes BM, et al. Patient-derived mammosphere and xenograft tumour initiation correlates with progression to metastasis. J Mammary Gland Biol Neoplasia. 2016;21(3–4):99–109. PubMedPubMedCentral Eyre R, Alferez DG, Spence K, Kamal M, Shaw FL, Simoes BM, et al. Patient-derived mammosphere and xenograft tumour initiation correlates with progression to metastasis. J Mammary Gland Biol Neoplasia. 2016;21(3–4):99–109. PubMedPubMedCentral
96.
Zurück zum Zitat Levin-Allerhand JA, Sokol K, Smith JD. Safe and effective method for chronic 17beta-estradiol administration to mice. Contemp Top Lab Anim Sci. 2003;42(6):33–5. PubMed Levin-Allerhand JA, Sokol K, Smith JD. Safe and effective method for chronic 17beta-estradiol administration to mice. Contemp Top Lab Anim Sci. 2003;42(6):33–5. PubMed
97.
Zurück zum Zitat Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989–98. PubMed Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989–98. PubMed
98.
Zurück zum Zitat Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, et al. Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance. BioRxiv The Preprint Server for Biology. 2020. Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, et al. Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance. BioRxiv The Preprint Server for Biology. 2020.
99.
Zurück zum Zitat Strom JO, Theodorsson A, Ingberg E, Isaksson IM, Theodorsson E. Ovariectomy and 17beta-estradiol replacement in rats and mice: a visual demonstration. J Vis Exp. 2012;64:e4013. Strom JO, Theodorsson A, Ingberg E, Isaksson IM, Theodorsson E. Ovariectomy and 17beta-estradiol replacement in rats and mice: a visual demonstration. J Vis Exp. 2012;64:e4013.
Metadaten
Titel
Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools
verfasst von
Erin D. Giles
Elizabeth A. Wellberg
Publikationsdatum
04.11.2020
Verlag
Springer US
Erschienen in
Journal of Mammary Gland Biology and Neoplasia / Ausgabe 4/2020
Print ISSN: 1083-3021
Elektronische ISSN: 1573-7039
DOI
https://doi.org/10.1007/s10911-020-09463-2

Weitere Artikel der Ausgabe 4/2020

Journal of Mammary Gland Biology and Neoplasia 4/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.